NanoViricides Inc. (NNVC)

[robi-1-kenobi]

This is what makes the technology so difficult which is what Dr. Seymour acknowledges.

Other posts by Nanopatent have provided more details. I haven't had time to read the source material, but I think it was cathepsin that was involved in removing the glycan caps.

In theory, adding cathepsin mimics to the 'Cide in addition to NPC1 mimic ligands could overcome that difficulty.

I would think that is why Dr. Diwan created multiple candidates for initial in vivo efficacy screening. Unfortunately, these same efficacy screens in vitro did not point to the lower efficacy they saw in vivo in the previous USAMRID testing of EbolaCide1.

I am not sure how they overcome that - maybe the in vitro efficacy results can be quantified and ranked?